Search reports.
Biosimilars Insulin Market size, Share, Growth 2031
Get free sample report Request for Customiztion Buy Now

Biosimilars Insulin Market size, Share, Growth 2031

Segments - Biosimilars Insulin Market by Types (Insulin Glargine Basaglar and Insulin Lantus), Applications (Type I Diabetes and Type II Diabetes), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031

https://growthmarketreports.com/raksha
Author : Raksha Sharma
https://growthmarketreports.com/Vaibhav
Fact-checked by : V. Chandola
https://growthmarketreports.com/Vishal
Editor : Vishal Golekar

Upcoming | Report ID :HC-760 | 4.4 Rating | 76 Reviews | 184 Pages | Format : PDF Excel PPT

Report Description


Biosimilars Insulin Market Outlook 2031

The Biosimilars Insulin Market size was USD 1.45 Billion in 2022 and is likely to reach USD 1.96 Billion by 2031, expanding at a CAGR of 3.4% during 2023–2031. The growth of the market is attributed to increasing number of diabetic patients.

Biosimilars is a biological product designed to have similar active properties to the one that has been previously licensed and has no clinically significant differences in terms of safety and effectiveness. Biosimilars insulin is a type of biosimilars where it is indistinguishable to the reference insulin product and is already been approved by FDA or licensed.

Biosimilars Insulin Market Key Takeaways

Biosimilars development represents a large profit potential for pharmaceutical manufacturers. Major insulin prouder has biosimilars as their patented product. Insulin was discovered ninety years back and even today therapy remains a staple of treatment for both type I and type II diabetes. Five main types of insulin are regular insulin, NPH, rapid-acting analogs, basal analogs, and pre-mixed insulin.

Regular insulin and NPH are synthetic form of naturally occurring human insulin. Insulin analogs are similar to human insulin but have their amino acid sequences altered to provide desired chemical properties. The WHO data shows that the maximum age group of the diabetics is 45 and above. The instruments in which the insulin is used are also relatively expensive.

  • Increasing number of diabetic patients worldwide is projected to drive the market.
  • High cost of the product is estimated to hinder the market growth.
  • Lack of awareness among the consumers act as major factor that hampers the market growth.
  • R&D investments and technological advancements in medical field are anticipated to create immense growth opportunities for the market players.

Scope of The Biosimilars Insulin Market Report

The report on the global biosimilars insulin market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Biosimilars Insulin Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2022

Historic Data

2016–2021

Forecast Period

2023–2031

Segmentation

Types (Insulin Glargine Basaglar and Insulin Lantus) and End Users (Type I Diabetes and Type II Diabetes)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Eli Lilly, Boehringer Ingelheim, Merck, Pfizer, Biocon, and Mylan.

Biosimilars Insulin Market Segment Insights

The insulin glargine basaglar segment is estimated to expand at a high CAGR

Based on type, the biosimilars insulin market is bifurcated into insulin glargine basaglar and insulin Lantus. The glargine basaglar insulin is projected to hold major market share. Basaglar is biologically similar to Sanofi's basal insulin Lantus (insulin glargine), including the same protein sequence and a similar glucose-lowering effect. While the FDA does not call it a “biosimilar” drug for regulatory reasons, it can essentially be thought of as an alternative form of Lantus. Insulin Lantus is also known as insulin glargine.

Biosimilars Insulin Market Types

The type I segment is estimated to hold major market share during the forecast period

On the basis of end users, the global biosimilar insulin market is bifurcated into type I diabetes and type II diabetes. Biosimilar insulin is used by type 1 and type 2 diabetes. Biosimilar insulin proved to have an effective treatment for patients suffering from diabetes mellitus by reducing the cost for the treatment. According to a report of World Health Organization (WHO), around 422 Mn adults are suffering from diabetes and around 1.5 million people have been killed by diabetes.

Biosimilars Insulin Market End Users

The market in North America is projected to hold a major market share

In terms of regions, the global biosimilars market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market in North America is subjected to hold major share in the biosimilars insulin market. This is because of the high number of diabetes patients in the region. The market in Asia Pacific is increasing due to rising number of patients in recent years in developing countries such as India and China.

Biosimilars Insulin Market By Regions

Segments

The global biosimilars insulin market is segmented on the basis of

Types

  • Insulin Glargine Basaglar
  • Insulin Lantus

End – Users

  • Type I Diabetes
  • Type II Diabetes

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe

Key Players

Competitive Landscape

The global biosimilars insulin market is highly competitive and major market players include Eli Lilly, Boehringer Ingelheim, Merck, Pfizer, Biocon, and Mylan. The global insulin biosimilars market has developed over the last few years. Companies are engaging in mergers, acquisitions and partnerships to extend their market share. Moreover they are focusing on expanding their product portfolio to leverage their market position.

In addition, many insulin manufacturing firms are likely to lose their patents quite soon, which is likely to offer ample growth opportunities for the global insulin biosimilars market. Increased investment by government agencies on the research and development activities pertaining to insulin biosimilars is providing ample scope of development for the market.

Biosimilars Insulin Market By Key Players

Table Of Content

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Biosimilars Insulin Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Biosimilars Insulin Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Biosimilars Insulin Market - Supply Chain
  4.5. Global Biosimilars Insulin Market Forecast
     4.5.1. Biosimilars Insulin Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Biosimilars Insulin Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Biosimilars Insulin Market Absolute $ Opportunity
5. Global Biosimilars Insulin Market Analysis and Forecast by Types
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Types
     5.2.2. Y-o-Y Growth Projections by Types
  5.3. Biosimilars Insulin Market Size and Volume Forecast by Types
     5.3.1. Insulin Glargine Basaglar
     5.3.2. Insulin Lantus
  5.4. Absolute $ Opportunity Assessment by Types
  5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Biosimilars Insulin Market Analysis and Forecast by End Users
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by End Users
     6.2.2. Y-o-Y Growth Projections by End Users
  6.3. Biosimilars Insulin Market Size and Volume Forecast by End Users
     6.3.1. Type I Diabetes
     6.3.2. Type II Diabetes
  6.4. Absolute $ Opportunity Assessment by End Users
  6.5. Market Attractiveness/Growth Potential Analysis by End Users
7. Global Biosimilars Insulin Market Analysis and Forecast by Region
  7.1. Market Trends
  7.2. Introduction
     7.2.1. Basis Point Share (BPS) Analysis by Region
     7.2.2. Y-o-Y Growth Projections by Region
  7.3. Biosimilars Insulin Market Size and Volume Forecast by Region
     7.3.1. North America
     7.3.2. Latin America
     7.3.3. Europe
     7.3.4. Asia Pacific
     7.3.5. Middle East and Africa (MEA)
  7.4. Absolute $ Opportunity Assessment by Region
  7.5. Market Attractiveness/Growth Potential Analysis by Region
  7.6. Global Biosimilars Insulin Demand Share Forecast, 2019-2026
8. North America Biosimilars Insulin Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
  8.2. North America Biosimilars Insulin Market Size and Volume Forecast by Country
     8.2.1. U.S.
     8.2.2. Canada
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. North America Biosimilars Insulin Market Size and Volume Forecast by Types
     8.4.1. Insulin Glargine Basaglar
     8.4.2. Insulin Lantus
  8.5. Basis Point Share (BPS) Analysis by Types
  8.6. Y-o-Y Growth Projections by Types
  8.7. North America Biosimilars Insulin Market Size and Volume Forecast by End Users
     8.7.1. Type I Diabetes
     8.7.2. Type II Diabetes
  8.8. Basis Point Share (BPS) Analysis by End Users
  8.9. Y-o-Y Growth Projections by End Users
  8.10. Market Attractiveness/Growth Potential Analysis
     8.10.1. By Country
     8.10.2. By Product Type
     8.10.3. By Application
  8.11. North America Biosimilars Insulin Demand Share Forecast, 2019-2026
9. Latin America Biosimilars Insulin Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Latin America Average Pricing Analysis
  9.2. Latin America Biosimilars Insulin Market Size and Volume Forecast by Country
      9.2.1. Brazil
      9.2.2. Mexico
      9.2.3. Rest of Latin America
   9.3. Absolute $ Opportunity Assessment by Country
  9.4. Latin America Biosimilars Insulin Market Size and Volume Forecast by Types
     9.4.1. Insulin Glargine Basaglar
     9.4.2. Insulin Lantus
  9.5. Basis Point Share (BPS) Analysis by Types
  9.6. Y-o-Y Growth Projections by Types
  9.7. Latin America Biosimilars Insulin Market Size and Volume Forecast by End Users
     9.7.1. Type I Diabetes
     9.7.2. Type II Diabetes
  9.8. Basis Point Share (BPS) Analysis by End Users
  9.9. Y-o-Y Growth Projections by End Users
  9.10. Market Attractiveness/Growth Potential Analysis
     9.10.1. By Country
     9.10.2. By Product Type
     9.10.3. By Application
  9.11. Latin America Biosimilars Insulin Demand Share Forecast, 2019-2026
10. Europe Biosimilars Insulin Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Europe Average Pricing Analysis
  10.2. Europe Biosimilars Insulin Market Size and Volume Forecast by Country
     10.2.1. Germany
     10.2.2. France
     10.2.3. Italy
     10.2.4. U.K.
     10.2.5. Spain
     10.2.6. Russia
     10.2.7. Rest of Europe
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Europe Biosimilars Insulin Market Size and Volume Forecast by Types
     10.4.1. Insulin Glargine Basaglar
     10.4.2. Insulin Lantus
  10.5. Basis Point Share (BPS) Analysis by Types
  10.6. Y-o-Y Growth Projections by Types
  10.7. Europe Biosimilars Insulin Market Size and Volume Forecast by End Users
     10.7.1. Type I Diabetes
     10.7.2. Type II Diabetes
  10.8. Basis Point Share (BPS) Analysis by End Users
  10.9. Y-o-Y Growth Projections by End Users
  10.10. Market Attractiveness/Growth Potential Analysis
     10.10.1. By Country
     10.10.2. By Product Type
     10.10.3. By Application
  10.11. Europe Biosimilars Insulin Demand Share Forecast, 2019-2026
11. Asia Pacific Biosimilars Insulin Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Asia Pacific Average Pricing Analysis
  11.2. Asia Pacific Biosimilars Insulin Market Size and Volume Forecast by Country
     11.2.1. China
     11.2.2. Japan
     11.2.3. South Korea
     11.2.4. India
     11.2.5. Australia
     11.2.6. Rest of Asia Pacific (APAC)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Asia Pacific Biosimilars Insulin Market Size and Volume Forecast by Types
     11.4.1. Insulin Glargine Basaglar
     11.4.2. Insulin Lantus
  11.5. Basis Point Share (BPS) Analysis by Types
  11.6. Y-o-Y Growth Projections by Types
  11.7. Asia Pacific Biosimilars Insulin Market Size and Volume Forecast by End Users
     11.7.1. Type I Diabetes
     11.7.2. Type II Diabetes
  11.8. Basis Point Share (BPS) Analysis by End Users
  11.9. Y-o-Y Growth Projections by End Users
  11.10. Market Attractiveness/Growth Potential Analysis
     11.10.1. By Country
     11.10.2. By Product Type
     11.10.3. By Application
  11.11. Asia Pacific Biosimilars Insulin Demand Share Forecast, 2019-2026
12. Middle East & Africa Biosimilars Insulin Market Analysis and Forecast
  12.1. Introduction
     12.1.1. Basis Point Share (BPS) Analysis by Country
     12.1.2. Y-o-Y Growth Projections by Country
     12.1.3. Middle East & Africa Average Pricing Analysis
  12.2. Middle East & Africa Biosimilars Insulin Market Size and Volume Forecast by Country
     12.2.1. Saudi Arabia
     12.2.2. South Africa
     12.2.3. UAE
     12.2.4. Rest of Middle East & Africa (MEA)
  12.3. Absolute $ Opportunity Assessment by Country
  12.4. Middle East & Africa Biosimilars Insulin Market Size and Volume Forecast by Types
     12.4.1. Insulin Glargine Basaglar
     12.4.2. Insulin Lantus
  12.5. Basis Point Share (BPS) Analysis by Types
  12.6. Y-o-Y Growth Projections by Types
  12.7. Middle East & Africa Biosimilars Insulin Market Size and Volume Forecast by End Users
     12.7.1. Type I Diabetes
     12.7.2. Type II Diabetes
  12.8. Basis Point Share (BPS) Analysis by End Users
  12.9. Y-o-Y Growth Projections by End Users
  12.10. Market Attractiveness/Growth Potential Analysis
     12.10.1. By Country
     12.10.2. By Product Type
     12.10.3. By Application
  12.11. Middle East & Africa Biosimilars Insulin Demand Share Forecast, 2019-2026
13. Competition Landscape
  13.1. Global Biosimilars Insulin Market: Market Share Analysis
  13.2. Biosimilars Insulin Distributors and Customers
  13.3. Biosimilars Insulin Market: Competitive Dashboard
  13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     13.4.1. Eli Lilly
     13.4.2. Boehringer Ingelheim
     13.4.3. Merck
     13.4.4. Pfizer
     13.4.5. Biocon
     13.4.6. Mylan

Methodology

Our Clients

General Mills
Pfizer
Siemens Healthcare
Microsoft
General Electric
Deloitte
The John Holland Group
sinopec